Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and ...

Availability of the revised financial statements for Sanofi excluding Opella Paris, France – . Following the press release on October 21, 2024 and the plan to transfer a ...

First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infections Two phase 1/2 clinical studies are ongoing to evaluate the safety ...

Many symptoms of MS are visible to the outside world, such as movement or speech problems, but there are also invisible symptoms (unseen by others) that significantly impact the lives of those living ...

Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or ...

Autoimmune type 1 diabetes (T1D) is an autoimmune progressive and lifelong condition that can develop regardless of age, lifestyle or family history. Individuals with autoimmune T1D are typically ...

The Meningitis Flag has been co-created with Meningitis Research Foundation (MRF), the Confederation of Meningitis Organisations (CoMO), Sanofi, and three para-athletes affected by the disease: Theo ...

This relic is a stark reminder of the fact that poliomyelitis existed just as long as human society. Polio, or poliomyelitis, is a crippling and potentially deadly infectious disease caused by the ...